Table 6.

Pharmacokinetic variables for cisplatin (platinum) and gemcitabine (dFdC and dFdU)

CompoundAll patients mean ± SD (n = 12)Twice-weekly bortezomib 1.0 mg/m2, mean ± SD (n = 6)Weekly bortezomib 1.0 mg/m2, mean ± SD (n = 6)P*
Platinum (plasma)
    Cmax, μmol/L11.0 ± 2.210.7 ± 1.411.3 ± 3.00.63
    AUC, min mmol/L50.0 ± 12.847.0 ± 8.852.9 ± 16.30.45
dFdC (plasma)
    Cmax day 1, μmol/L48.7 ± 14.947.6 ± 15.150.0 ± 16.40.81
    Cmax day 8, μmol/L50.5 ± 24.744.6 ± 17.956.3 ± 30.60.44
    AUC day 1 (0-60 min) min · μmol/L§1,441 ± 3761,398 ± 3571,491 ± 4340.71
    AUC day 8 (0-60 min) min · μmol/L§1,516 ± 6661,369 ± 5151,662 ± 8120.45
dFdU (plasma)
    Cmax day 1, μmol/L98.6 ± 13.8100.1 ± 11.197.2 ± 17.10.74
    Cmax day 8, μmol/L102.1 ± 23.2106.6 ± 23.297.7 ± 24.50.53
    AUC day 1 (0-60 min) min · μmol/L3,850 ± 6413,938 ± 5643,763 ± 7540.66
    AUC day 8 (0-60 min) min · μmol/L4,163 ± 1,1094,189 ± 1,2054,137 ± 1,1200.94
  • Abbreviation: AUC, area under the concentration curve.

  • * Twice-weekly compared with weekly bortezomib.

  • n = 11.

  • n = 5.

  • § Partial area under the concentration curve (0-60 min) was used to compare the pharmacokinetic profiles of dFdC and dFdU on days 1 and 8.

  • n = 6.

  • Partial area under the concentration curve (0-60 min) was used to compare the pharmacokinetic profiles of dFdC and dFdU on days 1 and 8.